79247-86-2

Basic information

• Product Name: 4-TRIFLUOROMETHYLTHIAZOLE-2-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 2-Thiazolecarboxylic acid, 4-(trifluoromethyl)-, ethyl ester;Ethyl 4-(trifluoromethyl)thiazole-2-carboxylate;Ethyl 4-(trifluoromethyl);thiazole-2-carboxylate;4-TRIFLUOROMETHYLTHIAZOLE-2-CARBOXYLIC ACID ETHYL ESTER
• CAS NO: 79247-86-2
• Molecular Formula: C₇H₆F₃NO₂S
• Molecular Weight: 225.1882496
• Mol File: 79247-86-2.mol

Chemical Properties

• Boiling Point: 239.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• PKA: -2.62±0.10(Predicted)
• CAS DataBase Reference: 4-TRIFLUOROMETHYLTHIAZOLE-2-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-TRIFLUOROMETHYLTHIAZOLE-2-CARBOXYLIC ACID ETHYL ESTER(79247-86-2)
• EPA Substance Registry System: 4-TRIFLUOROMETHYLTHIAZOLE-2-CARBOXYLIC ACID ETHYL ESTER(79247-86-2)

Safety Data

• Hazardous Substances Data: 79247-86-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-TRIFLUOROMETHYLTHIAZOLE-2-CARBOXYLIC ACID ETHYL ESTER is used as a reactant for the preparation of 2-acylaminothiazole derivatives. These derivatives serve as muscarinic M3 receptor positive allosteric modulators, which are important in the development of drugs targeting various therapeutic applications, such as treating respiratory diseases, gastrointestinal disorders, and other conditions where modulation of the muscarinic M3 receptor is beneficial.

Upstream product

• 64-17-5 ethanol 
• 431-35-6 3-bromo-1,1,1-trifluoroacetone 
• 16982-21-1 ethyl 2-amino-2-thioxoacetate 
• 51216-90-1 ethyl 2-thiooxamate 
• 421-50-1 1,1,1-trifluoro-2-propanone 

Downstream Products

• 1251166-18-3 4-chloro-6-(4-methoxybenzyloxy)-2-(4-trifluoromethylthiazol-2-yl)pyrimidine 
• 1251166-88-7 4-(4-methoxybenzyloxy)-6-phenoxy-2-(4-trifluoromethylthiazol-2-yl)pyrimidine 
• 1251166-89-8 5-phenoxy-2-(4-trifluoromethylthiazol-2-yl)pyrimidin-4-ol 
• 1251166-25-2 6-(4,5-dimethylthiazol-2-yl)-4-(4-methoxybenzyloxy)-2-(4-trifluoromethylthiazol-2-yl)pyrimidine 
• 1251166-34-3 4-(4-methoxybenzyloxy)-6-(5-methylthiophen-2-yl)-2-(4-trifluoromethylthiazol-2-yl)pyrimidine 
• 204319-69-7 (4-(trifluoromethyl)thiazol-2-yl)methanol 
• 1251166-37-6 4-(4-methoxybenzyloxy)-6-(5-trifluoromethylthiophen-2-yl)-2-(4-trifluoromethylthiazol-2-yl)pyrimidine 
• 1251166-87-6 6-phenoxy-2-(4-trifluoromethylthiazol-2-yl)pyrimidin-4-ol 
• 79247-85-1 4-Trifluoromethyl-thiazole-2-carboxylic acid methyl ester 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

LIVER X RECEPTORS (LXR) MODULATORS

The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXR?) and act preferably as inverse agonists of LXR.

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF

[Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.

HETEROCYCLIC COMPOUND

Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF

[Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M 3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, for example, voiding dysfunctions such as underactive bladder.

MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Dehydroamino acids

Compounds of formula 1 and 1-1, wherein R1 is hydrogen, hydroxy, amino or halogen, R2 is hydrogen, hydroxy, or halogen and R3 is hydrogen (Formula 1) or R1 is hydrogen and R2 and R3 taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is R4 R5 are hydrogen, methyl, ethyl or halogen except that R4 r5 cannot both be hydrogen; and 1) B is hydrogen, or lower alkyl; or 2) B is where R6 R7 R8 and R9 are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro; or 3) B is where R10 is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino; 4) B is where X and Y are independently methylene or nitrogen; or 5) B is where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or 6) B is where Y is carbon or nitrogen; or 7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.

An Infrared Study of Rotational Isomerism in Thiazole-2-carboxylates

A series of alkyl thiazole-2-carboxylates containing a range of substituents at the 4- and 5-positions has been prepared.Solutions of these esters (mostly new compounds) show well resolved doublets in the i.r.C=O region which arise from rotational isomers.The higher wavenumber components are assigned to the more polar carbonyl O,S-anti-s-trans-rotamers and the lower wavenumber components to the carbonyl O,S-syn-s-trans-forms.Small, but systematic, differences between the methyl esters are noted.